Skip to main content
OpenTrials
Completed

NCT Number: NCT05946499

Evaluation of Vitamin A and E Deficiency With Severity of SARS-COV-2 Disease: A Case-Control Study

Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has been spreading worldwide Coronaviridae study group of the International Committee on taxonomy of viruses (2020). The clinical manifestation of COVID-19 can range from asymptomatic infection to critical illness with severe pneumonia, respiratory failure, and death.

Vitamin A is of special interest in the field of infectious diseases, especially for pulmonary infections. It is crucial for the development of normal lung tissue and tissue repair after injury due to infection. Therefore, it may play a role in recovery after severe COVID-19 pneumonia. Vitamin A has immune regulatory functions and positively affects both the innate and adaptive immune cell response.

The anti-oxidant Vitamin E, and trace element selenium, are major components of anti-oxidant defense. Epidemiological studies demonstrate that deficiencies in, either of these nutrients, alters immune responses and viral pathogenicity.

Data concerning vitamin A and E plasma levels in COVID-19 patients are lacking. Therefore, this study aims at characterizing vitamin A and E plasma levels in COVID-19 and analyzing the association of plasma levels with disease severity and outcome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

balsam Sherif Fahmy

Cairo, None Selected, 11511, Egypt

About this study

The aim of the current study is to evaluate the relation of plasma level of Vitamin A and E and their correlation with severity of SARS-COV2 disease.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID-19 positive patients by PCR (polymerase chain reaction) test
  • Patients aging 18 to 75 years

Exclusion criteria

  • Patients with known immunodeficiency - Patients with known lung diseases

Treatment and study plan

Primary outcomes

  1. Correlating between vitamin A and E deficiency and severity of SARS-COV2

    Time frame: From September 2021 to November 2022

    Evaluation of vitamin A and E deficiency with COVID-19 disease severity

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Correlation Between Vitamin A and E Deficiency With Severity of SARS-COV2 Disease.

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jul 14, 2023
Registry last updated
Aug 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.